Acura Pharma Cmn (ACUR) 1.91 $ACUR What Awaits ACUR &

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acura Pharma Cmn (ACUR) 1.91 $ACUR

What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), NVLS: 4.76 (+0.08), CYTR: 0.60 (-0.05), CEMP: 18.50 (+0.53), ACUR: 1.91 (-0.03), NVS: 83.07 (-0.19)

Acura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities
Marketwire Canada - Wed Jun 08, 3:15PM CDT
Topline Results From Study AP-LTX-400 Cohort 2
ACUR: 1.91 (-0.03)

Egalet Settles Patent Litigations with Purdue Pharma
PR Newswire - Mon May 23, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet", a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that it has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for OXAYDO® (oxycodone HCl, USP) tablets CII. In April 2015 and April 2016 Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. filed patent infringement lawsuits against Egalet for OXAYDO alleging the product infringes Purdue's U.S. Patent No. 8,389,007 and U.S. Patent No. 9,308,171, respectively. Purdue has agreed to dismiss the complaints and both parties have agreed not to pursue any further action on OXAYDO, an immediate-release opioid product. There are no financial obligations to either party.
EGLT: 7.02 (-0.37), ACUR: 1.91 (-0.03)

Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Marketwired - Mon May 02, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016.
EGLT: 7.02 (-0.37), ACUR: 1.91 (-0.03)

Indiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem
Marketwired - Thu Apr 28, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced that, today, Indiana Governor Mike Pence will formally sign legislation designed to address and slow the "home-grown" meth problem in Indiana. The new law, known as Senate Enrolled Act 80, requires state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. The law requires rule and policy making by the Indiana Board of Pharmacy, including the determination of products that are meth-resistant. Upon enactment, pharmacists who do not have a relationship with a customer may, at their discretion after consultation with the customer, sell only a methamphetamine-resistant pseudoephedrine product such as Nexafed®, or a minimal supply of a traditional pseudoephedrine product. The new bill will go into effect on July 1, 2016 and will be signed at Webb's Family Pharmacy in Rochester, Ind.
ACUR: 1.91 (-0.03)

Acura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology
Marketwired - Tue Apr 26, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 9,320,796 by the United States Patent and Trademark Office pertaining to the Company's Limitx(TM) Technology platform.
ACUR: 1.91 (-0.03)

Acura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016
Marketwired - Thu Apr 21, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the first quarter 2016 following the close of financial markets on Monday, May 2, 2016. The Company will host a conference call to discuss the results on Tuesday, May 3, 2016 at 8:30 a.m. ET.
ACUR: 1.91 (-0.03)

Acura Pharmaceutical's Limitx(TM) Technology Successfully Demonstrates Oral Abuse Deterrence
Marketwired - Wed Apr 13, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline interim results from clinical study AP-LTX-400 demonstrated one test formulation of LTX-04, a hydromorphone hydrochloride immediate-release tablet using the Company's new LIMITX oral abuse deterrent technology, successfully demonstrated the release of the active opioid ingredient was reduced when three intact tablets were ingested but that additional formulation development will be required for LTX-04 to deliver a sufficient amount of the active ingredient to patients when one or two tablets are administered. Study AP-LTX-400 is a two cohort pharmacokinetic study with today's results limited to the first of the two cohorts. The second cohort of the study is expected to commence later this month.
ACUR: 1.91 (-0.03)

Acura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04
Marketwired - Tue Apr 12, 3:15PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of LTX-04, Acura's hydromorphone HCl tablets utilizing its oral abuse deterrent LIMITX technology, for the management of pain in patients where an opioid analgesic is appropriate.
ACUR: 1.91 (-0.03)

Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective
Marketwired - Wed Mar 30, 3:10PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that its universal shelf registration statement on Form S-3, as amended, was declared effective by the Securities and Exchange Commission (SEC) today.
ACUR: 1.91 (-0.03)

Acura Pharmaceuticals Acknowledges Inclusion of Meth-Resistant Technology in Indiana Legislation
Marketwired - Mon Mar 14, 3:10PM CDT
On Thursday, March 10, 2016 the Indiana General Assembly passed legislation to require state pharmacists to use professional discretion when selling pseudoephedrine-based cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. The Indiana bill has been sent to Indiana Governor Mike Pence for his signature and will require rule and policy making by the Indiana Board of Pharmacy, including the determination of products that are meth-resistant. If the bill is enacted, pharmacists who do not have a relationship with a customer may, at their discretion after consultation with the customer, sell only a methamphetamine resistant pseudoephedrine product such as Nexafed®, or a minimal supply of a traditional pseudoephedrine product.
ACUR: 1.91 (-0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 13

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 131

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

Delicious New Dips by Dean's Perfect for Every Snack Lovers

Updated Category News Views 536

Dean's Dip Launches Five Exciting New Flavors Dean's Dip, a well-loved name in the dairy dip sector, is thrilled to introduce its latest flavors, catering to snack aficionados everywhere. In addition to its classic offerings, the brand is now adding two delightful new dips — Creamy Dill and Jalapeño Popper. But that's not all! A fresh sub-line of dips, the Cantina...

Continue Reading
Bavarian Nordic Secures $63 Million for Vaccine Manufacturing

Updated Category News Views 102

Bavarian Nordic Secures New Contract with U.S. Government Bavarian Nordic A/S (Copenhagen: BAVA) has announced an important contract with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). This order, worth USD 63 million, will enhance the nation's stockpile of smallpox/mpox vaccines and pave the way for producing more freeze-dried doses...

Continue Reading
NewtekOne, Inc. Declares Impressive Quarterly Dividend Update

Updated Category News Views 158

NewtekOne, Inc. Announces Quarterly Dividend Declaration NewtekOne, Inc. (NASDAQ: NEWT) has recently made an exciting announcement for its shareholders. The Board of Directors has declared a quarterly cash dividend amounting to $0.19 per share, which is a testament to the company's ongoing commitment to enhancing shareholder value. As the company gears up for this...

Continue Reading
New Clean Freak Car Wash Location Welcomes Local Community

Updated Category News Views 516

Exciting New Location of Clean Freak Car Wash Clean Freak Car Wash, an innovative company supported by Circle K, is thrilled to announce the grand opening of its latest location. This highly anticipated launch is set to bring exceptional car wash services, designed to provide customers with a refreshing and satisfying experience. Commitment to Quality and Eco-Friendly...

Continue Reading
Bernie Sanders Calls for Action Against Wealth Inequality Surge

Updated Category News Views 200

Bernie Sanders Raises Concerns Over Wealth Disparity Sen. Bernie Sanders has openly criticized the increasing wealth inequality in the country, highlighting the significant gains of a select group of billionaires. His latest remarks reflect deep concern for the financial struggles faced by millions of Americans. Wealth of Billionaires on the Rise In a striking statement,...

Continue Reading